The Stem Cell Institute

What The Stem Cell Institute does

The Stem Cell Institute is a privately held, Panama-based regenerative medicine clinic founded in 2005 by Neil Riordan, PA, PhD, that provides stem cell therapy and ancillary regenerative treatments to international patients on a direct-to-consumer medical tourism basis. Its core offering is a treatment protocol built around Golden Cells™, a proprietary allogeneic mesenchymal stem cell product (hUCT-MSCs) derived from six molecularly selected cell lines sourced from donated human umbilical cord tissue. Treatments are administered at the BICSA Tower clinic in Panama City (physically connected to the Hilton Panama, with VIP airport and concierge services bundled into pricing), while cell production and quality control are handled in-house at the affiliated Medistem Panama laboratory — an 11,000 sq. ft., ISO 9001-certified, GMP-compliant facility housing 75+ employees including 15 quality control specialists.

The business model is a fee-for-service medical practice with unit pricing per treatment protocol rather than a product or licensing revenue stream. Pricing is disclosed publicly: entry-level pediatric protocols start at approximately $15,890, adult protocols at approximately $26,900, and tiered Wellness & Longevity packages (Essential and Advanced) include diagnostics and adjunctive services. Revenue is generated from direct payments by patients who apply online, complete a virtual consultation, and travel to Panama City for in-person treatment spanning typically 3-5 days of infusions or injections. Adjacent services include the cell-free MTF (Mesenchymal Trophic Factors) therapy containing exosomes and 300+ bioactive molecules, deliverable via IV, intramuscular, intra-articular, intrathecal, intranasal, or nebulizer routes. The company is privately held, reports no external institutional funding, and does not publicly disclose revenue figures.

Target patient segments are diversified across neurological and neurodevelopmental conditions (autism, multiple sclerosis, cerebral palsy), autoimmune diseases (rheumatoid arthritis, lupus), cardiovascular conditions (heart failure), orthopedic and musculoskeletal issues (osteoarthritis, sports injuries), and — more recently — wellness and longevity use cases targeting health-conscious adult consumers. The company cites 80,000+ cumulative procedures performed on 15,000+ unique patients over its operating history, with no serious adverse events reported. Academic and research relationships span multiple universities (UC San Diego, University of Utah, University of Western Ontario, University of Florida, University of Massachusetts, University of Costa Rica), and founder Neil Riordan's affiliated entities (Medistem Panama, Aidan Products, Signature Biologics, Arugula Sciences) suggest an ecosystem-level operation spanning clinic, laboratory, biologics products, and a US FDA-authorized IND (16026) for Duchenne's muscular dystrophy.

Name

The Stem Cell Institute

Legal name

Stem Cell Institute

Website

https://cellmedicine.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Stem Cell Institute is a privately held Panama-based regenerative medicine clinic offering proprietary Golden Cells™ mesenchymal stem cell therapy for chronic conditions including autism, MS, autoimmune diseases, heart failure, and orthopedic issues, plus wellness programs, treating 15,000+ patients through a direct-to-consumer medical tourism model.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Cell Therapy Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Stem cell therapy
• Regenerative medicine
• Mesenchymal stem cells
• Medical tourism
• Cell-based treatments

Headquarters

HQ city

Panama City

HQ country

Panama

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Stem Cell Therapy Treatments: Direct patient payments for stem cell therapy procedures. Treatment fees include the medical procedure plus hotel accommodation at Hilton Panama with breakfast, WIFI, airport transportation with VIP gate service, and expedited customs clearance. Fees vary by condition and protocol.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

The Stem Cell Institute operates a stem cell therapy clinic in Panama City, Panama, providing autologous and allogeneic mesenchymal stem cell treatments to patients worldwide. Founded by Neil Riordan, PA, PhD, the clinic administers its proprietary Golden Cells™ product to address a range of conditions including autism spectrum disorder, multiple sclerosis, autoimmune diseases, heart failure, sports injuries, and general wellness/longevity. Patients travel to Panama to receive treatment packages priced from approximately $15,890 to $26,900+ depending on the protocol.

Product overview

Stem Cell Institute is a global leader in stem cell research and treatment, offering a portfolio of regenerative medicine therapies centered around its proprietary Golden Cells™ — human umbilical cord tissue-derived mesenchymal stem cells. The company provides condition-specific treatment protocols for chronic diseases (autism, multiple sclerosis, autoimmune diseases, heart failure), acute conditions (sports injuries), and wellness/anti-aging programs. Supporting services include MTF (Mesenchymal Trophic Factors) therapy as a cell-free adjunct, with all cells processed in-house at the ISO 9001-certified Medistem Panama laboratory. Treatment protocols are protocol-driven, spanning 3-5 days with multiple administration methods (IV, intramuscular, intrathecal, intra-articular, intranasal).

Differentiator

Problem solved

Functional benefit

Brands

• Golden Cells™: Proprietary mesenchymal stem cells derived from human umbilical cord tissue, developed through years of research and retrospective analysis of successful patient outcomes. Exclusive to Stem Cell Institute.

Products and services

• Stem Cell Therapy for Autism Spectrum Disorder

Quantifiable outcome

• 80,000+ procedures performed safely with no serious adverse events reported among 15,000+ patients treated
• +2 more outcomes

Named customers10 records

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• University of California, San DiegocoreStrategic or Co-development PartnerAcademic research collaboration with university researchers on stem cell science and clinical applications.
• University of UtahcoreStrategic or Co-development PartnerAcademic collaboration for stem cell research and clinical trials.
• University of Western OntariocoreStrategic or Co-development PartnerAcademic partnership for stem cell research and scientific publications.
• University of FloridacoreStrategic or Co-development PartnerResearch collaboration in stem cell therapy development.
• University of MassachusettscoreStrategic or Co-development PartnerAcademic partnership for stem cell science and clinical research.
• University of Costa RicacoreStrategic or Co-development PartnerRegional academic collaboration for stem cell research.
• Medistem PanamacoreTechnology or IntegrationSeparate but affiliated company founded by Dr. Neil Riordan. Operates the ISO 9001-certified, GMP-compliant laboratory that processes and produces all stem cells used at Stem Cell Institute. Medistem and SCI work closely under Dr. Riordan's scientific direction.
• Hilton Panama HotelminorStrategic or Co-development PartnerPreferred hotel partner located in the same building (BICSA Tower) as Stem Cell Institute clinic. Hotel rooms included in treatment packages for patient convenience.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Regenexx: Largest US-based network of stem cell and platelet-rich plasma treatment clinics focused primarily on orthopedic and musculoskeletal indications; overlaps SCI's orthopedic, sports-injury, and arthritis patient segments.
• Global Stem Cells Group: International stem cell and regenerative medicine clinic operator with locations in Latin America and the US offering MSC-based therapies; competes for similar cash-pay patient populations and indications.
• StemGenex: US-based (San Diego) autologous stem cell treatment clinic historically focused on adipose-derived therapies for chronic conditions; comparable cash-pay direct-to-consumer stem cell clinic model.
• Celltex Therapeutics: Houston/Mexico-based stem cell therapy company offering autologous MSC banking and treatment across similar indications (autoimmune, orthopedic, neurological); comparable medical-tourism business model serving US patients abroad.
• Okyanos Cell Therapy: Bahamas-based adult stem cell clinic delivering autologous and culture-expanded stem cell therapies for heart, orthopedic, and autoimmune conditions; competes with SCI in the Caribbean cross-border stem cell treatment market.
• BioXcellerator: Colombia- and Panama-based regenerative medicine clinic offering allogeneic MSC and exosome therapies for orthopedic, autoimmune, neurological, and longevity conditions; directly competes with SCI for international cash-pay stem cell patients in Latin America.

Broad incumbents

• Mesoblast: FDA-registered MSC-based cell therapy developer (remestemcel-L, rexlemestrocel) for pediatric SR-aGvHD and chronic inflammatory conditions; represents the regulated drug-development counterpart of SCI's clinic-administered MSC approach.

Emerging players

• Bluebird Bio: Gene and cell therapy developer advancing approved and clinical-stage therapies (e.g., sickle cell, beta-thalassemia, cerebral adrenoleukodystrophy); competitive technology backdrop in the pediatric/neurological indications SCI's autism/CP patients seek treatment for.

Others

• UC San Diego / University of Utah research collaborations: Academic collaborators on SCI clinical research; OTHERS category because they are R&D enablers rather than commercial competitors, but the published collaborations underpin SCI's scientific credibility.
• Hilton Panama (BICSA): On-site hotel partner at BICSA Tower where SCI clinic is co-located; not a peer but a key distribution/infrastructure partner enabling SCI's concierge-based medical tourism model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/Stemcellspanama
• LinkedInlinkedin.com/company/the-institute-for-cellular-medicine-the-stem-cell-institute

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Stem Cell Institute